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Abstract
INTRODUCTION: Advanced methods of treating pancreatic cancer are being explored to minimize some 
of the adversities associated with traditional laparoscopy. One of the most promising procedures is robotic 
duodenopancreatectomy, which appears to reduce morbidity, mortality, conversion rate, hospital stay, and improve 
oncological results among patients. As such, the procedure is gaining popularity in several medical facilities.
AIM: The article describes robotic duodenopancreatectomy, improved surgical treatment of pancreatic cancer that 
involves the use of augmented reality.
MATERIALS AND METHODS: The study involves a systematic review of existing literature on robotic 
duodenopancreatectomy. A total of 16 scholarly articles, published within the past 5 years, are used to synthesize 
information designed to provide a conclusive summary of evidence related to robotic duodenopancreatectomy. All 
the materials are retrieved from two medical databases, MEDLINE and ProQuest.
RESULTS/OUTCOME: Morbidity: The rate of morbidity associated with the procedure is relatively high, up to 40%, 
but slightly lower compared to open laparoscopy, which exhibits morbidity rates of approximately 75%. Mortality: There 
is evidence of incidences of mortality in robotic duodenopancreatectomy, ranging between 1 and 12.5%. The main 
cause of death associated with the procedure is post-pancreatic hemorrhage. Conversion rate: The conversion rate 
in robotic surgery is relatively lower compared to open laparoscopy, ranging between 0 and 37.5%. However, it can 
decrease to 33.3% after subsequent surgeries. Hospital stay: The procedure is associated with a shorter hospital stays 
(13.7–24 days) compared to open laparoscopy (25.8 days). Oncological outcomes: Robotic duodenopancreatectomy 
lacks clear oncological results. However, few studies have established a median overall survival of 15 months. 
CONCLUSION: Given that robotic duodenopancreatectomy reduces the rates of mortality, morbidity, conversion 
rate, and length of hospital stays, it appears to be an ideal treatment of pancreatic cancer.
Introduction
One of the medical operations with promising 
results of reducing mortality rates among pancreatic 
cancer patients is duodenopancreatectomy, also known 
as pancreaticoduodenectomy (PD) or the Whipple’s 
procedure. PD is universally accepted and regarded as 
the sole chance of survival for patients with tumors of the 
head of the pancreas, malignant periampullary tumors, 
distal cholangiocarcinoma, and cancer of the first and 
second portions of the duodenum [1]. Over the years, the 
procedure has been improved to incorporate the growth 
in augmented reality devices to enhance the outcomes 
of the open PD [2], [3]. As a result of this technological 
improvement, robotic duodenopancreatectomy is 
gaining popularity in the field of medicine.
Robotic duodenopancreatectomy refers to the 
use of robotic platforms in the treatment of pancreatic 
cancer, such as the Vinci surgical system. The practice 
requires a remarkable mastery of the facets used in the 
robotic system, including optimal port placement and 
accurate coordination between the remotely located 
console and the surgeon cart [4]. While performing 
the PD resection, the surgeon controls the platform 
through a system console that is located separately 
from the patient and displayed in the vision cart for 
assistant surgeons to view and manage the process 
[5]. The required instruments are then attached to 
the arms of the robot, which is in the patient’s cart 
and navigated from the central surgeon console [6]. 
The process allows the medical practitioner to have a 
better view of the area under surgery. Joyce adds that 
the approach enables the physician to have a three-
dimensional stereoscopic observation, whereby the 
visuals of the head of the pancreas, duodenum, and 
other surrounding tissues are displayed as an output 
for each eye, making it easier to locate critical vascular 
structures [7]. Thus, robotic duodenopancreatectomy 
is perceived to be an accurate form of laparoscopic 
surgery.
The article describes robotic 
duodenopancreatectomy, improved surgical treatment 
of pancreatic cancer that involves the use of augmented 
reality. Data obtained from the current literature are 
used to build on clinical knowledge regarding morbidity, 
mortality, conversion rate, hospital stay, and oncological 
results associated with the procedure.
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Morbidity
While robot facilitated surgery is an attractive 
option for the treatment of pancreatic cancer, concerns over 
chances of morbidity associated with the procedure are 
always evident. Although the practice has been enhanced 
since the 1930s, the perioperative morbidity rates remain 
relatively high, approximately 30% [8]. Other studies 
reveal high rates of up to 40% [1]. Nonetheless, research 
shows that cases of morbidity in robotic facilitated surgery 
are lower compared to those of open PD [9]. For instance, 
a systematic review conducted by Kornaropoulos showed 
a significant difference between the two approaches, 
whereby robotic PD and open PD were recorded at 25% 
and 75% in one study, and 40% and 67% in another, 
respectively [1]. In addition, Zimmerman et al. discovered 
that the procedure did not increase 30-day morbidity [10]. 
However, scholarly exploration by Wang et al. and Aziz 
et al. resulted in contradicting outcomes [1], [11]. The 
data collected showed that no substantial differences 
in morbidity between open and robotic laparoscopic 
approaches were evident [12], [13]. These statistics 
reveal that despite the prevalence of morbidity in robotic 
duodenopancreatectomy, the outcome is promising 
compared to that of open laparoscopy.
Majority of the incidents of morbidity in robotic 
duodenopancreatectomy result from post-operative 
fistula (POPF). McEvoy defines this condition as a 
“drain output of amylase-rich fluid” (8, p. 3). In a study 
conducted by Giulianotti, the incidences of POPF stood 
at 31.6% among patients undergoing robotic PD [2]. 
Nahm et al. solidified this aspect through a review of 
the previous research, which revealed that 41% of 
morbidity cases after pancreatic resection are caused 
by POPF [14]. However, some surgeons have registered 
successful procedures that were free of this condition.
Mortality
The complexity of robotic PD may sometimes 
lead to fatality. Some studies report incidences of robotic 
PD mortality ranging from 1% to 12.5% [1]. Although 
there has been a reduction in blood loss associated 
with the robotic procedure, a large portion of these 
deaths still arises from post-pancreatic hemorrhage. 
While the procedure is perceived as accurate, some 
mishaps may lead to broken vascular structures, 
especially considering the proximity of the pancreas to 
blood vessels. However, evidence shows that the risks 
of hemorrhagic complications are higher in institutions 
with less experienced surgeons [15]. Therefore, medical 
facilities that offer such complex services are required 
to have a competent workforce that can operate the 
several facets of the robotic system. In addition, medical 
practitioners are expected to incorporate some of the 
new and improved therapies, such as palliative radiation, 
to prevent excessive blood loss during surgery.
Conversion rate
Based on data from the previous studies, 
it is evident that the conversion rate in robotic PD is 
relatively lower compared to open PD. The average 
rate of conversion in most pancreatic robotic surgeries 
ranges from 0% to 18.3% and 0% to 37.5% [1], [10]. 
Some of the common indicators of conversion rate 
include hemorrhage and failure of the patient to 
respond to treatment. However, research also shows 
that the conversion rate can reduce after subsequent 
operations. For instance, the rate of conversion in one 
of the clinical trials dropped from 33% to 3.3% after 20 
procedures [1]. The above information proves that the 
robotic system is a feasible procedure for the treatment 
of PD.
Hospital stay
Robotic PD is associated with short lengths of 
hospital stays (LOS). The previous studies show that 
the mean LOS after robot facilitated surgery is 13.7–
24 days [1]. In other researches, the average duration 
after the procedure was recorded at 10 days [1]. 
Shorter LOS in the robotic system may be associated 
with reduced morbidities, such as hemorrhagic 
complications and fewer cases of cardiac events, thus 
allowing the patient to leave the hospital a few days 
after the surgery. In comparison with open PD, robotic 
PD has shorter LOS, whereby the former exhibits 
average stays of up to 25.8 days [1]. Hence, robot 
facilitated surgery is highly recommended as a means 
of reducing health-care costs related to prolonged 
hospital stays.
Oncological Results
Studies are yet to establish substantial long-
term oncological outcomes of robotic pancreatic 
surgery. According to Tanaka et al., the major challenge 
involved in obtaining significant results is failure of 
researchers to follow-up on patients, thus making it 
difficult to report on survival data [16]. In addition, the 
author argues that a selection bias exists, whereby 
fewer patients with oncological diagnoses are selected 
for the procedure [16]. However, multiple attempts 
by scholars to record oncological results in the past 
few years are available. For instance, Giulianotti et al. 
reported a median overall survival (OS) of 15 months 
among 10 patients that underwent robotic surgery [16]. 
Besides, a study showed an OS of 1–45 months among 
72 patients [16]. The above results reveal that robotic PD 
enhances the chances of survival among patients with 
pancreatic cancer.
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Conclusion
Robotic PD portrays promising outcomes in 
the treatment of pancreatic cancer. The procedure not 
only reduces the rates of mortality and morbidity but 
also the length of hospital stays. In addition, robotic PD 
is perceived to enhance surgical accuracy compared 
to open PD, thus reducing cases of excessive blood 
loss. If performed by experienced medical personnel, 
health complications such as hemorrhage can be 
prevented. However, the most significant challenge that 
stakeholders are likely to face in the adoption of the 
system is the high costs of acquiring the equipment, 
which translates to expensive medical services among 
pancreatic cancer patients.
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